These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

560 related items for PubMed ID: 25900871

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
    Kelly EM, Tungol AA, Wesolowicz LA.
    J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
    [Abstract] [Full Text] [Related]

  • 3. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A, Winterholer S, Jeitler K, Horvath K, Berghold A, Krenn C, Semlitsch T.
    Cochrane Database Syst Rev; 2021 Jan 17; 1(1):CD007654. PubMed ID: 33454957
    [Abstract] [Full Text] [Related]

  • 4. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
    Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S.
    JAMA; 2016 Jun 14; 315(22):2424-34. PubMed ID: 27299618
    [Abstract] [Full Text] [Related]

  • 5. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A, Jeitler K, Horvath K, Berghold A, Posch N, Meschik J, Semlitsch T.
    Cochrane Database Syst Rev; 2016 Mar 02; 3():CD007654. PubMed ID: 26934640
    [Abstract] [Full Text] [Related]

  • 6. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
    Shyh G, Cheng-Lai A.
    Cardiol Rev; 2014 Mar 02; 22(1):43-50. PubMed ID: 24304809
    [Abstract] [Full Text] [Related]

  • 7. Obesity Pharmacotherapy.
    Saunders KH, Umashanker D, Igel LI, Kumar RB, Aronne LJ.
    Med Clin North Am; 2018 Jan 02; 102(1):135-148. PubMed ID: 29156182
    [Abstract] [Full Text] [Related]

  • 8. Current and emerging pharmacotherapies for obesity in Australia.
    Hocking S, Dear A, Cowley MA.
    Obes Res Clin Pract; 2017 Jan 02; 11(5):501-521. PubMed ID: 28818558
    [Abstract] [Full Text] [Related]

  • 9. A Comparison of New Pharmacological Agents for the Treatment of Obesity.
    Nuffer W, Trujillo JM, Megyeri J.
    Ann Pharmacother; 2016 May 02; 50(5):376-88. PubMed ID: 26887340
    [Abstract] [Full Text] [Related]

  • 10. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
    Tak YJ, Lee SY.
    Curr Obes Rep; 2021 Mar 02; 10(1):14-30. PubMed ID: 33410104
    [Abstract] [Full Text] [Related]

  • 11. Overview of new antiobesity drugs.
    Hainer V.
    Expert Opin Pharmacother; 2014 Oct 02; 15(14):1975-8. PubMed ID: 25100293
    [Abstract] [Full Text] [Related]

  • 12. Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out.
    Citrome L.
    Int J Clin Pract; 2014 Dec 02; 68(12):1401-5. PubMed ID: 25418525
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. New obesity agents: lorcaserin and phentermine/topiramate.
    Fleming JW, McClendon KS, Riche DM.
    Ann Pharmacother; 2013 Dec 02; 47(7-8):1007-16. PubMed ID: 23800750
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. ACS chemical neuroscience molecule spotlight on Qnexa.
    Mercer SL.
    ACS Chem Neurosci; 2011 Apr 20; 2(4):183-4. PubMed ID: 22778866
    [Abstract] [Full Text] [Related]

  • 18. Fixed-dose combination of phentermine-topiramate for the treatment of obesity.
    Halpern B, Faria AM, Halpern A.
    Expert Rev Clin Pharmacol; 2013 May 20; 6(3):235-41. PubMed ID: 23656337
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.